|
WINNIPEG, Manitoba – February 1, 2012 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today that its PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test has been cleared for sale by Health Canada.
Read More
|
|
Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that its PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test has now been CE Marked and is officially registered within the European Union. CE Marking allows the PreVu POC test to be marketed in the European Union for coronary artery disease risk assessment screening for use within the general population.
Read More
|
|
WINNIPEG, Manitoba – January 20, 2012 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces it has agreed to issue 952,533 common shares to Genesys Venture Inc., at a price of $0.0675 per common share (net cash value of $64,296), as payment for services rendered in accordance with the terms of an agreement between the parties.
Read More
|
WINNIPEG, Manitoba – January 17th, 2012 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today that it has filed a class II medical device license application with Health Canada for the PreVu Non-Invasive Skin Cholesterol Point of Care (POC) Test. The application, in significant part, required that Miraculins develop an ISO 13485 certified Quality Management System. Miraculins was issued its formal ISO Certificate of Registration by The BSI Group Inc. on January 13, 2012.
Read More
|
|
WINNIPEG, Manitoba – January 12th, 2012 - Miraculins Inc.
(TSX-V:MOM), a medical diagnostic company focused on developing and
commercializing diagnostic tests and risk assessment technologies for
unmet clinical needs, is pleased to announce that Alere Inc. (formerly
Inverness Medical Innovations) has secured its second exclusive option
period on Miraculins’ preeclampsia technology and will provide
Miraculins a non-refundable fee in accordance with the terms of the
Collaborative Research and Option Agreement between the parties. Alere,
in partnership with Miraculins, is working towards the goal of
commercializing Miraculins’ preeclampsia technology for worldwide
distribution.
Read More
|
|
|